Search

Your search keyword '"Martinelli, Giovanni"' showing total 5,057 results
Start Over Author "Martinelli, Giovanni"
5,057 results on '"Martinelli, Giovanni"'

351. Poster: AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Author

Perl, Alexander E, primary, Altman, Jessica K, additional, Hosono, Naoko, additional, Montesinos, Pau, additional, Podoltsev, Nikolai, additional, Martinelli, Giovanni, additional, Smith, Catherine C, additional, Levis, Mark J, additional, Röllig, Christoph, additional, Groß-Langenhoff, Marco, additional, Hasabou, Nahla, additional, Lu, Qiaoyang, additional, and Tiu, Ramon V, additional

Published
2021
Full Text
View/download PDF

354. Safety of FLT3 inhibitors in patients with acute myeloid leukemia

Author

Cerchione, Claudio, primary, Peleteiro Raíndo, Andrés, additional, Mosquera Orgueira, Adrián, additional, Mosquera Torre, Alicia, additional, Bao Pérez, Laura, additional, Marconi, Giovanni, additional, Isidori, Alessandro, additional, Pérez Encinas, Manuel Mateo, additional, and Martinelli, Giovanni, additional

Published
2021
Full Text
View/download PDF

356. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Author

Lin, Wei-Yu, primary, Fordham, Sarah E, additional, Hungate, Eric, additional, Sunter, Nicola J, additional, Elstob, Claire, additional, Xu, Yaobo, additional, Park, Catherine, additional, Quante, Anne, additional, Strauch, Konstantin, additional, Gieger, Christian, additional, Skol, Andrew, additional, Rahman, Thahira, additional, Sucheston-Campbell, Lara, additional, Wang, Junke, additional, Hahn, Theresa, additional, Clay-Gilmour, Alyssa I, additional, Jones, Gail L, additional, Marr, Helen J, additional, Jackson, Graham H, additional, Menne, Tobias, additional, Collin, Mathew, additional, Ivey, Adam, additional, Hills, Robert K, additional, Burnett, Alan K, additional, Russell, Nigel H, additional, Fitzgibbon, Jude, additional, Larson, Richard A, additional, Le Beau, Michelle M, additional, Stock, Wendy, additional, Heidenreich, Olaf, additional, Alharbi, Abrar, additional, Allsup, David J, additional, Houlston, Richard S, additional, Norden, Jean, additional, Dickinson, Anne M, additional, Douglas, Elisabeth, additional, Lendrem, Clare, additional, Daly, Ann K, additional, Palm, Louise, additional, Piechocki, Kim, additional, Jeffries, Sally, additional, Bornhäuser, Martin, additional, Röllig, Christoph, additional, Altmann, Heidi, additional, Ruhnke, Leo, additional, Kunadt, Desiree, additional, Wagenführ, Lisa, additional, Cordell, Heather J, additional, Darlay, Rebecca, additional, Andersen, Mette K, additional, Fontana, Maria C, additional, Martinelli, Giovanni, additional, Marconi, Giovani, additional, Sanz, Miguel A, additional, Cervera, José, additional, Gómez-Seguí, Inés, additional, Cluzeau, Thomas, additional, Moreilhon, Chimène, additional, Raynaud, Sophie, additional, Sill, Heinz, additional, Voso, Maria Teresa, additional, Lo-Coco, Francesco, additional, Dombret, Hervé, additional, Cheok, Meyling, additional, Preudhomme, Claude, additional, Gale, Rosemary E, additional, Linch, David, additional, Gaal-Wesinger, Julia, additional, Masszi, Andras, additional, Nowak, Daniel, additional, Hofmann, Wolf-Karsten, additional, Gilkes, Amanda, additional, Porkka, Kimmo, additional, Milosevic Feenstra, Jelena D, additional, Kralovics, Robert, additional, Grimwade, David, additional, Meggendorfer, Manja, additional, Haferlach, Torsten, additional, Krizsán, Szilvia, additional, Bödör, Csaba, additional, Stölzel, Friedrich, additional, Onel, Kenan, additional, and Allan, James M, additional

Published
2021
Full Text
View/download PDF

358. Lineage‐specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture

Author

Liverani, Chiara, primary, De Vita, Alessandro, additional, Spadazzi, Chiara, additional, Miserocchi, Giacomo, additional, Cocchi, Claudia, additional, Bongiovanni, Alberto, additional, De Lucia, Anna, additional, La Manna, Federico, additional, Fabbri, Francesco, additional, Tebaldi, Michela, additional, Amadori, Dino, additional, Tasciotti, Ennio, additional, Martinelli, Giovanni, additional, Mercatali, Laura, additional, and Ibrahim, Toni, additional

Published
2021
Full Text
View/download PDF

359. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Author

Maifrede, Silvia, primary, Le, Bac Viet, additional, Nieborowska-Skorska, Margaret, additional, Golovine, Konstantin, additional, Sullivan-Reed, Katherine, additional, Dunuwille, Wangisa M.B., additional, Nacson, Joseph, additional, Hulse, Michael, additional, Keith, Kelsey, additional, Madzo, Jozef, additional, Caruso, Lisa Beatrice, additional, Gazze, Zachary, additional, Lian, Zhaorui, additional, Padella, Antonella, additional, Chitrala, Kumaraswamy N., additional, Bartholdy, Boris A., additional, Matlawska-Wasowska, Ksenia, additional, Di Marcantonio, Daniela, additional, Simonetti, Giorgia, additional, Greiner, Georg, additional, Sykes, Stephen M., additional, Valent, Peter, additional, Paietta, Elisabeth M., additional, Tallman, Martin S., additional, Fernandez, Hugo F., additional, Litzow, Mark R., additional, Minden, Mark D., additional, Huang, Jian, additional, Martinelli, Giovanni, additional, Vassiliou, George S., additional, Tempera, Italo, additional, Piwocka, Katarzyna, additional, Johnson, Neil, additional, Challen, Grant A., additional, and Skorski, Tomasz, additional

Published
2021
Full Text
View/download PDF

360. Abstract 2776: Sequential immunohistochemistry and computational image analysis for a deeper characterization of tumor-infiltrating myeloid cells

Author

Tumedei, Maria Maddalena, primary, Piccinini, Filippo, additional, Bulgarelli, Jenny, additional, Guidoboni, Massimo, additional, Limarzi, Francesco, additional, Vergani, Barbara, additional, Leone, Biagio Eugenio, additional, Puccetti, Maurizio, additional, Bravaccini, Sara, additional, Martinelli, Giovanni, additional, Ibrahim, Toni, additional, and Tazzari, Marcella, additional

Published
2021
Full Text
View/download PDF

364. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Author

Daver, Naval G., Dail, Monique, Garcia, Jacqueline S., Jonas, Brian A., Yee, Karen W. L., Kelly, Kevin R., Vey, Norbert, Assouline, Sarit, Roboz, Gail J., Paolini, Stefania, Pollyea, Daniel A., Tafuri, Agostino, Brandwein, Joseph M., Pigneux, Arnaud, Powell, Bayard L., Fenaux, Pierre, Olin, Rebecca L., Visani, Giuseppe, Martinelli, Giovanni, Onishi, Maika, Wang, Jue, Huang, Weize, Green, Cherie, Ott, Marion G., Hong, Wan-Jen, Konopleva, Marina Y., and Andreeff, Michael

Abstract

This phase 1b trial (NCT02670044) evaluated venetoclax-idasanutlin in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic chemotherapy. Two-dimensional dose escalation (DE, n = 50) was performed for venetoclax daily with idasanutlin on days 1 to 5 in 28-day cycles, followed by dosing schedule optimization (n = 6) to evaluate reduced venetoclax schedules (21-/14-day dosing). Common adverse events (occurring in ≥40% of patients) included diarrhea (87.3% of patients), nausea (74.5%), vomiting (52.7%), hypokalemia (50.9%), and febrile neutropenia (45.5%). During DE, across all doses, composite complete remission (CRc; CR + CR with incomplete blood count recovery + CR with incomplete platelet count recovery) rate was 26.0% and morphologic leukemia-free state (MLFS) rate was 12%. For anticipated recommended phase 2 doses (venetoclax 600 mg + idasanutlin 150 mg; venetoclax 600 mg + idasanutlin 200 mg), the combined CRc rate was 34.3% and the MLFS rate was 14.3%. Pretreatment IDH1/2 and RUNX1 mutations were associated with higher CRc rates (50.0% and 45.0%, respectively). CRc rate in patients with TP53 mutations was 20.0%, with responses noted among those with co-occurring IDH and RUNX1 mutations. In 12 out of 36 evaluable patients, 25 emergent TP53 mutations were observed; 22 were present at baseline with low TP53 variant allele frequency (median 0.0095% [range, 0.0006-0.4]). Venetoclax-idasanutlin showed manageable safety and encouraging efficacy in unfit patients with R/R AML. IDH1/2 and RUNX1 mutations were associated with venetoclax-idasanutlin sensitivity, even in some patients with co-occurring TP53 mutations; most emergent TP53 clones were preexisting. Our findings will aid ongoing/future trials of BCL-2/MDM2 inhibitor combinations. This trial was registered at www.clinicaltrials.gov as #NCT02670044.

Published
2023
Full Text
View/download PDF

365. Evidence of late-Holocene mud-volcanic eruptions in the Modena foothills (northern Italy)

Author

Falsone Gloria, Lisa Borgatti, Mainardi Giuseppe, Bosi Giovanna, Cremonini Stefano, Montecchi Maria Chiara, Martinelli Giovanni, Labate Donato, Guandalini Francesca, Pieraccini Diego, Bracci Antonio Edoardo, and Borgatti L., Bosi G., Bracci A. E., Cremonini S., Falsone G., Guandalini F. , Labate D., Mainardi G., Martinelli G., Montecchi M.C., Pieraccini D.

Subjects
Archeology, Global and Planetary Change, geography, geography.geographical_feature_category, Ecology, Geoarchaeology, Earth science, Paleontology, Montegibbio, Northern italy, Volcano, mud volcano, northern Apennines, Minerva goddess, Natural hazard, Foothills, geoarchaeology, geochemistry, Minerva goddess, Montegibbio, mud volcano, northern Apennines, geoarchaeology, Temporal scales, Geology, Holocene, geochemistry, Earth-Surface Processes, Mud volcano
Abstract

Among natural hazards, mud volcanoes can damage property and infrastructures and affect hillslope evolution at different spatial and temporal scales. The results of 10-year-long multidisciplinary investigations performed on a Roman-age archaeological site, La Rovina di Montegibbio, are presented, showing a peculiar example of mutual interplay between human settlement and geological forcing in the mud-volcanic environment. The site (350 m a.s.l.) lies at the termination of the upper Secchia River catchment, near the town of Sassuolo (Modena Province). Here, a 4-km-long mud volcano belt borders the Apennines chain front, comprising one of the most prominent mud volcanoes of Italy ( Salsa di Montegibbio), and the still-active chain hinge tectonics gives origin to gas and oil seeps. Based on geological, geoarchaeological, palaeobotanical, geochemical, geophysical records and analytical data, we unravel the onset, the evolution and the abandonment of the settlement in relation to the existence of a previously unknown mud volcano, belonging to the larger Montegibbio mud volcano system. The damages affecting the Roman-age buildings record the ground deformations in the context of mud volcano tectonics. In particular, the pattern of faults set buried under the archaeological site is shown and compared with that of the main mud volcano conduit. At least two Roman-age eruptive episodes have been recorded, whose ejected muds are geochemically characterized. The first recorded eruption must be regarded as the reason for the initial location and function of the sacred ancient settlement. The final site abandonment was because of subsequent severe ground deformations affecting the hillslope as a consequence of mud volcano activity.

Published
2019

366. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

Author

Gökbuget, Nicola, Dombret, Hervé, Giebel, Sebastian, Bruggemann, Monika, Doubek, Michael, Foà, Robin, Hoelzer, Dieter, Kim, Christopher, Martinelli, Giovanni, Parovichnikova, Elena, Rambaldi, Alessandro, Ribera, Jose-Maria, Schoonen, Marieke, Stieglmaier, Julia M., Zugmaier, Gerhard, Bassan, Renato, and Universitat Autònoma de Barcelona

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Lymphoblastic Leukemia, Acute lymphoblastic leukemia, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, hemic and lymphatic diseases, Internal medicine, Ph Negative, Humans, Medicine, Philadelphia Chromosome, Aged, business.industry, Minimal residual disease, Hematopoietic Stem Cell Transplantation, hemic and immune systems, Hematology, Middle Aged, Allografts, Allogeneic stem cell transplant, Europe, Survival Rate, body regions, MRD, 030220 oncology & carcinogenesis, Female, business, Follow-Up Studies, 030215 immunology
Abstract

Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4 Methods: Study population was from ALL study groups in Europe managed in national study protocols 2000–2014. MRD was measured by polymerase chain reaction or flow cytometry. Patients were age ≥15 years at initial ALL diagnosis. Patients were excluded if exposed to blinatumomab within 18 months of baseline or prior alloHSCT. Results: Of 272 patients in CR1, baseline MRD was ≥10−1, 10−2 to −1, 10−3 to −2, and 10−4 to −3 in 15 (6%), 71 (26%), 109 (40%), and 77 (28%) patients, respectively. Median duration of complete remission (DoR) was 18.5 months (95% confidence interval [CI], 11.9–27.2), median relapse-free survival (RFS) was 12.4 months (95% CI, 10.0–19.0) and median overall survival (OS) was 32.5 months (95% CI, 23.6–48.0). Lower baseline MRD level (P ≤ .0003) and white blood cell count P ≤ .0053) were strong predictors for better RFS and DoR. Allogeneic hematopoietic stem cell transplantation (alloHSCT) was associated with longer RFS (hazard ratio [HR], 0.59; 95% CI, 0.41–0.84) and DoR (HR, 0.43; 95% CI, 0.29–0.64); the association with OS was not significant (HR, 0.72; 95% CI, 0.50–1.05). Discussion: In conclusion, RFS, DoR, and OS are relatively short in patients with MRD-positive ALL, particularly at higher MRD levels. AlloHSCT may improve survival but has limitations. Alternative approaches are needed to improve outcomes in MRD-positive ALL.

Published
2019

367. Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

Author

Nicolini, Franck E., Mauro, Michael J., Martinelli, Giovanni, Kim, Dong-Wook, Soverini, Simona, Müller, Martin C., Hochhaus, Andreas, Cortes, Jorge, Chuah, Charles, Dufva, Inge H., Apperley, Jane F., Yagasaki, Fumiharu, Pearson, Jay D., Peter, Senaka, Sanz Rodriguez, Cesar, Preudhomme, Claude, Giles, Francis, Goldman, John M., and Zhou, Wei

Published
2009
Full Text
View/download PDF

368. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34− cell population with intrinsic resistance to imatinib

Author

Lemoli, Roberto M., Salvestrini, Valentina, Bianchi, Elisa, Bertolini, Francesco, Fogli, Miriam, Amabile, Marilina, Tafuri, Agostino, Salati, Simona, Zini, Roberta, Testoni, Nicoletta, Rabascio, Cristina, Rossi, Lara, Martin-Padura, Ines, Castagnetti, Fausto, Marighetti, Paola, Martinelli, Giovanni, Baccarani, Michele, Ferrari, Sergio, and Manfredini, Rossella

Published
2009
Full Text
View/download PDF

369. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Author

Rosti, Gianantonio, Palandri, Francesca, Castagnetti, Fausto, Breccia, Massimo, Levato, Luciano, Gugliotta, Gabriele, Capucci, Adele, Cedrone, Michele, Fava, Carmen, Intermesoli, Tamara, Cambrin, Giovanna Rege, Stagno, Fabio, Tiribelli, Mario, Amabile, Marilina, Luatti, Simona, Poerio, Angela, Soverini, Simona, Testoni, Nicoletta, Martinelli, Giovanni, Alimena, Giuliana, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, and GIMEMA CML Working Party

Published
2009
Full Text
View/download PDF

370. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

Author

Testoni, Nicoletta, Marzocchi, Giulia, Luatti, Simona, Amabile, Marilina, Baldazzi, Carmen, Stacchini, Monica, Nanni, Mauro, Rege-Cambrin, Giovanna, Giugliano, Emilia, Giussani, Ursula, Abruzzese, Elisabetta, Kerim, Simonetta, Grimoldi, Maria Grazia, Gozzetti, Alessandro, Crescenzi, Barbara, Carcassi, Carlo, Bernasconi, Paolo, Cuneo, Antonio, Albano, Francesco, Fugazza, Giuseppina, Zaccaria, Alfonso, Martinelli, Giovanni, Pane, Fabrizio, Rosti, Gianantonio, and Baccarani, Michele

Published
2009
Full Text
View/download PDF

371. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)

Author

Iacobucci, Ilaria, Storlazzi, Clelia Tiziana, Cilloni, Daniela, Lonetti, Annalisa, Ottaviani, Emanuela, Soverini, Simona, Astolfi, Annalisa, Chiaretti, Sabina, Vitale, Antonella, Messa, Francesca, Impera, Luciana, Baldazzi, Carmen, D'Addabbo, Pietro, Papayannidis, Cristina, Lonoce, Angelo, Colarossi, Sabrina, Vignetti, Marco, Piccaluga, Pier Paolo, Paolini, Stefania, Russo, Domenico, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, Foà, Robin, and Martinelli, Giovanni

Published
2009
Full Text
View/download PDF

372. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Author

Harousseau, Jean-Luc, Martinelli, Giovanni, Jedrzejczak, Wieslaw W., Brandwein, Joseph M., Bordessoule, Dominique, Masszi, Tamas, Ossenkoppele, Gert J., Alexeeva, Julia A., Beutel, Gernot, Maertens, Johan, Vidriales, Maria-Belen, Dombret, Hervé, Thomas, Xavier, Burnett, Alan K., Robak, Tadeusz, Khuageva, Nuriet K., Golenkov, Anatoly K., Tothova, Elena, Mollgard, Lars, Park, Youn C., Bessems, Annick, De Porre, Peter, and Howes, Angela J.

Published
2009
Full Text
View/download PDF

373. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up

Author

Mosna, Federico, Papayannidis, Cristina, Martinelli, Giovanni, Di Bona, Eros, Bonalumi, Angela, Tecchio, Cristina, Candoni, Anna, Capelli, Debora, Piccin, Andrea, Forghieri, Fabio, Bigazzi, Catia, Visani, Giuseppe, Zambello, Renato, Zanatta, Lucia, Volpato, Francesca, Paolini, Stefania, Testoni, Nicoletta, Gherlinzoni, Filippo, and Gottardi, Michele

Published
2015
Full Text
View/download PDF

374. Germline polymorphisms and survival of lung adenocarcinoma patients: A genome-wide study in two European patient series

Author

Galvan, Antonella, Colombo, Francesca, Frullanti, Elisa, Dassano, Alice, Noci, Sara, Wang, Yufei, Eisen, Timothy, Matakidou, Athena, Tomasello, Luisa, Vezzalini, Marzia, Sorio, Claudio, Dugo, Matteo, Ambrogi, Federico, Iacobucci, Ilaria, Martinelli, Giovanni, Incarbone, Matteo, Alloisio, Marco, Nosotti, Mario, Tosi, Davide, Santambrogio, Luigi, Pelosi, Giuseppe, Pastorino, Ugo, Houlston, Richard S., and Dragani, Tommaso A.

Published
2015
Full Text
View/download PDF

375. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi

Author

Rossi, Giuseppe, Marcheselli, Luigi, Dondi, Alessandra, Bottelli, Chiara, Tucci, Alessandra, Luminari, Stefano, Arcaini, Luca, Merli, Michele, Pulsoni, Alessandro, Boccomini, Carola, Puccini, Benedetta, Micheletti, Moira, Martinelli, Giovanni, Rossi, Andrea, Zilioli, Vittorio Ruggero, Bozzoli, Valentina, Balzarotti, Monica, Bolis, Silvia, Cabras, Maria Giuseppina, and Federico, Massimo

Published
2015
Full Text
View/download PDF

376. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Author

Baccarani, Michele, Rosti, Gianantonio, Castagnetti, Fausto, Haznedaroglu, Ibrahim, Porkka, Kimmo, Abruzzese, Elisabetta, Alimena, Giuliana, Ehrencrona, Hans, Hjorth-Hansen, Henrik, Kairisto, Veli, Levato, Luciano, Martinelli, Giovanni, Nagler, Arnon, Lanng Nielsen, Johan, Ozbek, Ugur, Palandri, Francesca, Palmieri, Fausto, Pane, Fabrizio, Rege-Cambrin, Giovanna, Russo, Domenico, Specchia, Giorgina, Testoni, Nicoletta, Weiss-Bjerrum, Ole, Saglio, Giuseppe, and Simonsson, Bengt

Published
2009
Full Text
View/download PDF

377. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

Author

Castagnetti, Fausto, Palandri, Francesca, Amabile, Marilina, Testoni, Nicoletta, Luatti, Simona, Soverini, Simona, Iacobucci, Ilaria, Breccia, Massimo, Rege Cambrin, Giovanna, Stagno, Fabio, Specchia, Giorgina, Galieni, Piero, Iuliano, Franco, Pane, Fabrizio, Saglio, Giuseppe, Alimena, Giuliana, Martinelli, Giovanni, Baccarani, Michele, Rosti, Gianantonio, and for the GIMEMA CML Working Party

Published
2009
Full Text
View/download PDF

380. Additional file 2 of Clinical research activities during COVID-19: the point of view of a promoter of academic clinical trials

Author

Valmorri, Linda, Vertogen, Bernadette, Zingaretti, Chiara, Miserocchi, Anna, Volpi, Roberta, Clemente, Alberto, Bondi, Isabella, Valli, Irene, Rudnas, Britt, Martinelli, Giovanni, and Nanni, Oriana

Abstract

Additional file 2: Supplementary Table S2. Monitoring visits and Site Initiation Visits (SIV) during the “pandemic period 2020” (11/03–30/06) and the same period in 2019.

Published
2021
Full Text
View/download PDF

382. Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation

Author

Terragna, Carolina, Renzulli, Matteo, Remondini, Daniel, Tagliafico, Enrico, Di Raimondo, Francesco, Patriarca, Francesca, Martinelli, Giovanni, Roncaglia, Enrica, Masini, Luciano, Tosi, Patrizia, Zamagni, Elena, Tacchetti, Paola, Ledda, Antonio, Brioli, Annamaria, Angelucci, Emanuele, Testoni, Nicoletta, Marzocchi, Giulia, Galieni, Piero, Gozzetti, Alessandro, Martello, Marina, Dico, Flores, Mancuso, Katia, and Cavo, Michele

Published
2013
Full Text
View/download PDF

383. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations

Author

Simonetti, Giorgia, primary, Mengucci, Carlo, additional, Padella, Antonella, additional, Fonzi, Eugenio, additional, Picone, Gianfranco, additional, Delpino, Claudio, additional, Nanni, Jacopo, additional, De Tommaso, Rossella, additional, Franchini, Eugenia, additional, Papayannidis, Cristina, additional, Marconi, Giovanni, additional, Pazzaglia, Martina, additional, Perricone, Margherita, additional, Scarpi, Emanuela, additional, Fontana, Maria Chiara, additional, Bruno, Samantha, additional, Tebaldi, Michela, additional, Ferrari, Anna, additional, Bochicchio, Maria Teresa, additional, Ghelli Luserna Di Rorà, Andrea, additional, Ghetti, Martina, additional, Napolitano, Roberta, additional, Astolfi, Annalisa, additional, Baldazzi, Carmen, additional, Guadagnuolo, Viviana, additional, Ottaviani, Emanuela, additional, Iacobucci, Ilaria, additional, Cavo, Michele, additional, Castellani, Gastone, additional, Haferlach, Torsten, additional, Remondini, Daniel, additional, Capozzi, Francesco, additional, and Martinelli, Giovanni, additional

Published
2021
Full Text
View/download PDF

384. An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study (Preprint)

Author

Passardi, Alessandro, primary, Serra, Patrizia, additional, Donati, Caterina, additional, Fiori, Federica, additional, Prati, Sabrina, additional, Vespignani, Roberto, additional, Taglioni, Gabriele, additional, Farfaneti Ghetti, Patrizia, additional, Martinelli, Giovanni, additional, Nanni, Oriana, additional, Altini, Mattia, additional, Frassineti, Giovanni Luca, additional, and Minguzzi, Martina Vittoria, additional

Published
2021
Full Text
View/download PDF

385. Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient

Author

Rossi, Tania, primary, Palleschi, Michela, additional, Angeli, Davide, additional, Tebaldi, Michela, additional, Martinelli, Giovanni, additional, Vannini, Ivan, additional, Puccetti, Maurizio, additional, Limarzi, Francesco, additional, Maltoni, Roberta, additional, Gallerani, Giulia, additional, and Fabbri, Francesco, additional

Published
2021
Full Text
View/download PDF

386. Tamoxifen protects breast cancer patients from COVID-19: first evidence from real world data

Author

Bravaccini, Sara, primary, Nicolini, Fabio, additional, Balzi, William, additional, Azzali, Irene, additional, Calistri, Arianna, additional, Parolin, Cristina, additional, Vitiello, Adriana, additional, Biasolo, Maria Angela, additional, Mazzotti, Lucia, additional, Gaimari, Anna, additional, Maltoni, Roberta, additional, Altini, Mattia, additional, Falcini, Fabio, additional, Montella, Maria Teresa, additional, Nanni, Oriana, additional, Ravaioli, Sara, additional, Pirini, Francesca, additional, Tumedei, Maria Maddalena, additional, Cortesi, Michela, additional, Zanoni, Michele, additional, Cerchione, Claudio, additional, Sambri, Vittorio, additional, Ibrahim, Toni, additional, Martinelli, Giovanni, additional, and Mazza, Massimiliano, additional

Published
2021
Full Text
View/download PDF

387. Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia

Author

Simonetti, Giorgia, primary, Angeli, Davide, additional, Petracci, Elisabetta, additional, Fonzi, Eugenio, additional, Vedovato, Susanna, additional, Sperotto, Alessandra, additional, Padella, Antonella, additional, Ghetti, Martina, additional, Ferrari, Anna, additional, Robustelli, Valentina, additional, Di Liddo, Rosa, additional, Conconi, Maria Teresa, additional, Papayannidis, Cristina, additional, Cerchione, Claudio, additional, Rondoni, Michela, additional, Astolfi, Annalisa, additional, Ottaviani, Emanuela, additional, Martinelli, Giovanni, additional, and Gottardi, Michele, additional

Published
2021
Full Text
View/download PDF

389. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

Author

Martino, Massimo, primary, Canale, Filippo Antonio, additional, Alati, Caterina, additional, Vincelli, Iolanda Donatella, additional, Moscato, Tiziana, additional, Porto, Gaetana, additional, Loteta, Barbara, additional, Naso, Virginia, additional, Mazza, Massimiliano, additional, Nicolini, Fabio, additional, Ghelli Luserna di Rorà, Andrea, additional, Simonetti, Giorgia, additional, Ronconi, Sonia, additional, Ceccolini, Michela, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Cerchione, Claudio, additional

Published
2021
Full Text
View/download PDF

390. Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer

Author

Rapposelli, Ilario Giovanni, primary, Zampiga, Valentina, additional, Cangini, Ilaria, additional, Arcangeli, Valentina, additional, Ravegnani, Mila, additional, Valgiusti, Martina, additional, Pini, Sara, additional, Tamberi, Stefano, additional, Bartolini, Giulia, additional, Passardi, Alessandro, additional, Martinelli, Giovanni, additional, Calistri, Daniele, additional, Frassineti, Giovanni Luca, additional, Falcini, Fabio, additional, and Danesi, Rita, additional

Published
2021
Full Text
View/download PDF

391. Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.

Author

Perl, Alexander E., primary, Larson, Richard A., additional, Podoltsev, Nikolai Alexandrovich, additional, Strickland, Stephen, additional, Wang, Eunice S., additional, Schiller, Gary J., additional, Martinelli, Giovanni, additional, Neubauer, Andreas, additional, Sierra, Jorge, additional, Montesinos, Pau, additional, Recher, Christian, additional, Yoon, Sung-Soo, additional, Hosono, Naoko, additional, Onozawa, Masahiro, additional, Chiba, Shigeru, additional, Kim, Hee-Je, additional, Hasabou, Nahla, additional, Lu, Qiaoyang, additional, Tiu, Ramon Velasquez, additional, and Levis, Mark J., additional

Published
2021
Full Text
View/download PDF

392. Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.

Author

Solomon, Scott R., primary, Montesinos, Pau, additional, Nazha, Aziz, additional, Strickland, Stephen Anthony, additional, Martinelli, Giovanni, additional, Santoro, Armando, additional, Walter, Roland B., additional, Cook, Rachel J., additional, Calbacho, Maria, additional, Vives, Susana, additional, Fazal, Salman, additional, Brzózka, Krzysztof, additional, Shamsili, Setareh, additional, Baldini, Simone, additional, Laurent, Dirk, additional, Pellacani, Andrea Ugo Enrico, additional, and Ravandi, Farhad, additional

Published
2021
Full Text
View/download PDF

395. Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer

Author

Tedaldi, Gianluca, primary, Molinari, Chiara, additional, São José, Celina, additional, Barbosa-Matos, Rita, additional, André, Ana, additional, Danesi, Rita, additional, Arcangeli, Valentina, additional, Ravegnani, Mila, additional, Saragoni, Luca, additional, Morgagni, Paolo, additional, Rebuzzi, Francesca, additional, Canale, Matteo, additional, Pignatta, Sara, additional, Ferracci, Elisa, additional, Martinelli, Giovanni, additional, Ranzani, Guglielmina Nadia, additional, Oliveira, Carla, additional, Calistri, Daniele, additional, and Ulivi, Paola, additional

Published
2021
Full Text
View/download PDF

396. Immunotherapy in Acute Myeloid Leukemia: Where We Stand

Author

Isidori, Alessandro, primary, Cerchione, Claudio, additional, Daver, Naval, additional, DiNardo, Courtney, additional, Garcia-Manero, Guillermo, additional, Konopleva, Marina, additional, Jabbour, Elias, additional, Ravandi, Farhad, additional, Kadia, Tapan, additional, Burguera, Adolfo de la Fuente, additional, Romano, Alessandra, additional, Loscocco, Federica, additional, Visani, Giuseppe, additional, Martinelli, Giovanni, additional, Kantarjian, Hagop, additional, and Curti, Antonio, additional

Published
2021
Full Text
View/download PDF

397. Exploring the ATR-CHK1 Pathway in the Response of Doxorubicin-induced DNA Damages in Acute Lymphoblastic Leukemia Cells

Author

Rorà, Andrea Ghelli Luserna di, primary, Ghetti, Martina, additional, Ledda, Lorenzo, additional, Ferrari, Anna, additional, Bocconcelli, Matteo, additional, Padella, Antonella, additional, Napolitano, Roberta, additional, Fontana, Maria Chiara, additional, Liverani, Chiara, additional, Imbrogno, Enrica, additional, Bochicchio, Maria Teresa, additional, Paganelli, Matteo, additional, Robustelli, Valentina, additional, Sanogo, Seydou, additional, Cerchione, Claudio, additional, Fumagalli, Monica, additional, Rondoni, Michela, additional, Imovilli, Annalisa, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Simonetti, Giorgia, additional

Published
2021
Full Text
View/download PDF

400. Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens

Author

Botta, Cirino, primary, Martino, Enrica Antonia, additional, Conticello, Concetta, additional, Mendicino, Francesco, additional, Vigna, Ernesto, additional, Romano, Alessandra, additional, Palumbo, Giuseppe Antonio, additional, Cerchione, Claudio, additional, Martinelli, Giovanni, additional, Morabito, Fortunato, additional, Di Raimondo, Francesco, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results